The compound demonstrates exceptional target selectivity, with no inhibition of related methyltransferases (DNMT1, PRMT3, COMT) or NAD+ salvage enzymes (NAMPT, SIRT1) at concentrations up to 600 M
Always speak with your doctor when taking any new medication or supplementation
Nausea (most common, typically dose-dependent and transient) Diarrhea or constipation during dose escalation Vomiting, especially when starting or increasing dose Reduced appetite and early satiety Injection site reactions (redness, bruising) Fatigue, particularly in early weeks Rare: Pancreatitis discontinue immediately with severe abdominal pain Rare: Thyroid C-cell effects (contraindicated with MEN2 or thyroid cancer history) AOD-9604 is a modified C-terminal fragment (residues 176191, Tyr-hGH177-191) of human growth hormone, studied for lipolytic and anti-obesity properties
AOD-9604 targets belly fat directly This happens because receptors in visceral fat tissue are particularly sensitive to the action of this peptide fragment
Delivery Methods Compared Both peptides are available in multiple delivery formats